Navigation Links
Covance Elects Bradley T. Sheares to Company's Board of Directors
Date:2/19/2009

PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that it has elected Bradley T. Sheares, Ph. D., to its Board of Directors.

Dr. Sheares is former chief executive officer and member of the Board of Directors of Reliant Pharmaceuticals, Inc., a pharmaceutical company that marketed a portfolio of branded cardiovascular medicines. Prior to joining Reliant, he was president of the U.S. Human Health division of Merck and Co., Inc., where he led commercial efforts in the United States for the company's portfolio of prescription medicines for the treatment of chronic and acute diseases. In addition to this role, Dr. Sheares was a member of Merck's management committee, which was responsible for formulating global business strategies, managing operations and setting corporate policies. He joined Merck in 1987 as research fellow in the Merck Research Laboratories, and he held positions of increasing responsibility in Merck until his departure in 2006.

"We are very pleased to welcome Dr. Sheares to our Board of Directors. His scientific background, academic achievements and extensive experience in bringing new medicines to the market will strengthen Covance's ability to provide innovative drug development solutions to our clients, " said Joe Herring, Covance chairman and CEO. "We look forward to leveraging Dr. Sheares' outstanding record of leadership and management, as well as his focus on recruiting top talent, to help our company sustain its leadership position in the industry and continue to provide value to our shareholders and employees."

"Covance has been at the forefront of creating innovative models of outsourcing," said Dr. Sheares. "I am thrilled at the opportunity to be part of such an accomplished group of individuals and to leverage my health care experience in enhancing the company's ability to deliver high-quality service and integrated solutions to its clients."

Dr. Sheares also serves on the Board of Directors of Honeywell International, a diversified technology and manufacturing company, and The Progressive Corporation, one of the nation's largest insurance holding companies. In addition, he serves on the Board of Trustees of Spelman College and is a member of the College of Physicians of Philadelphia, the Abington Friends School Committee, the Scientific Advisory Council for Montclair State University, and the Executive Leadership Council. He is the former chair of the Board of Directors of the National Pharmaceutical Council, which focuses on broadly communicating the economic, clinical and societal value of pharmaceuticals.

Dr. Sheares graduated summa cum laude with a bachelor's degree in chemistry from Fisk University and earned his doctorate in biochemistry from Purdue University. He completed his postdoctoral training as a Lucille P. Markey Scholar and NIH Research Fellow at the Massachusetts Institute of Technology.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 20 countries, and more than 9,600 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Covance to Present at the 2009 UBS Global Healthcare Services Conference
2. Covance Opens Three New Offices in Ukraine, Slovakia, and Israel
3. Covance Reports Fourth Quarter and Full-Year 2008 Results
4. Covance to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2008 Financial Results Conference Call
6. Covance Inc. Invites You to Join the Webcast of Its 2009 Guidance Conference Call
7. Covance to Present at the Credit Suisse 2008 Healthcare Conference
8. Covance and Lilly Enter Into a Strategic R&D Collaboration
9. Covance Recognized for Outstanding Performance by Merck & Co., Inc.
10. Covance Recognized for Outstanding Customer Service by Eli Lilly and Company
11. Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2008 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Aliso Viejo, CA (PRWEB) , ... February 18, ... ... styled animating paragraph presets. Use Pixel Film Studios ’ ProParagraph Fashion ... listings, descriptions, and so many other applications. Users can pick and choose ...
(Date:2/17/2017)... Ocala, FL (PRWEB) , ... February 17, 2017 ... ... of software tools that allow for the electronic prescribing of controlled and non-controlled ... , Ninety percent of pharmacies in the United States now accept electronic ...
(Date:2/17/2017)... ... 17, 2017 , ... Qualis Health, one of the nation's ... Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that ... multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... 2017 , ... PrideStaff, a national staffing organization, is pleased ... Industry Analysts' 2017 "Staffing 100 North America" list. , Now in its ... the staffing industry over the last twelve months. Industry insiders and observers nominate ...
(Date:2/17/2017)... ... 2017 , ... Dillon Ruxton Insurance, a Florida-based agency offering ... the greater Fort Lauderdale metropolitan region, is embarking on a cooperative food drive ... LifeNet 4 Families has provided a broad range of food provision services to ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... -- DaVita Inc. (NYSE: DVA ) today announced ... Net income attributable to DaVita Inc. for ... million, or $0.80 per share and $880 million, or $4.29 ... to DaVita Inc. for the quarter and year ended December ... million, or $0.98 per share, and $789 million, or $3.85 ...
(Date:2/16/2017)... ST. LOUIS , Feb. 16, 2017  Express Scripts (NASDAQ: ... one of the World,s Most Admired Companies within the Health Care: ... to be named one of the World,s Most Admired Companies," said ... is driven by the commitment and passion of our 26,000 employees ... people we serve." ...
(Date:2/16/2017)... , Feb 16, 2017 Research and Markets ... Diagnostics Market Analysis & Trends - Function, Application, Cancer Type, Technology ... ... Cancer Diagnostics Market is poised to grow at a CAGR of ... by 2025. Some of the prominent trends ...
Breaking Medicine Technology: